Product Information

OXTELLAR XR 300 MG TABLET is a brand product labeled by Supernus Pharmaceuticals Inc., priced at $12.7495 per EA under NDC 17772012201. Its NADAC has been published 674 times since Dec 18, 2013.

FDA first approved this application on Oct 19, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the OXCARBAZEPINE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

OXTELLAR XR 300 MG TABLET

OXCARBAZEPINE
$12.7495per EA
High Outlier

Strength

300 mg/1

NDC

17772012201

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Effective Date

10/21/2026

Active Ingredients

OXCARBAZEPINE

Approval Type

New Drug (NDA)

FDA Application

NDA202810

FDA Approved

10/19/2012

TE Code

AB

On Market Since

1/17/2013

Pharmacological Classes

Anti-epileptic Agent
Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for OXTELLAR XR 300 MG TABLET has been published 674 times since Dec 18, 2013, and over the history we have for it it has risen 215.2%. The table below summarizes its recorded NADAC range and movement.

Current price$12.7495 per EA
All-time high$12.7554 (Aug 13, 2025)
All-time low$4.0446 (Dec 18, 2013)
52-week high$12.7549
52-week low$12.6995
Median price$9.5424
Average price$9.2049
Largest weekly change+13.9% (Jul 23, 2014)
Weeks tracked674
Tracking sinceDec 18, 2013

Price History

1W

0.0%

1M

-0.0%

3M

-0.0%

6M

-0.0%

1Y

+0.3%

3Y

+12.6%

5Y

+26.5%

All

+215.2%

Generic Alternatives

The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of OXTELLAR XR 300 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for OXTELLAR XR 300 MG TABLET, manufactured by Supernus Pharmaceuticals Inc., is $12.7495 per EA (NDC 17772012201), effective Nov 11, 2026.

How has the price of OXTELLAR XR 300 MG TABLET changed over time?

Over the history we have for it, the NADAC for OXTELLAR XR 300 MG TABLET has risen 215.2%. It has been tracked across 674 weekly CMS publications since Dec 18, 2013.

What are the highest and lowest recorded NADAC prices for OXTELLAR XR 300 MG TABLET?

Since Dec 18, 2013, the NADAC for OXTELLAR XR 300 MG TABLET has ranged from a low of $4.0446 (Dec 18, 2013) to a high of $12.7554 (Aug 13, 2025), with a median of $9.5424 per EA.

Are there cheaper alternatives to OXTELLAR XR 300 MG TABLET?

Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OXCARBAZEPINE 300 MG TABLET, is $0.1714 per EA — about 99% below OXTELLAR XR 300 MG TABLET.

Who manufactures OXTELLAR XR 300 MG TABLET?

OXTELLAR XR 300 MG TABLET (NDC 17772012201) is labeled by Supernus Pharmaceuticals Inc., and CMS classifies it as a brand product.